ID: ALA165875

Max Phase: Preclinical

Molecular Formula: C15H11N3O6S

Molecular Weight: 361.33

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN(c1nc2ccccc2c(=O)o1)S(=O)(=O)c1ccc([N+](=O)[O-])cc1

Standard InChI:  InChI=1S/C15H11N3O6S/c1-17(15-16-13-5-3-2-4-12(13)14(19)24-15)25(22,23)11-8-6-10(7-9-11)18(20)21/h2-9H,1H3

Standard InChI Key:  RVBJLIXVRSKZML-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 361.33

Molecular Weight (Monoisotopic): 361.0369

AlogP: 1.92

#Rotatable Bonds: 4

Polar Surface Area: 123.62

Molecular Species: NEUTRAL

HBA: 7

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa:

CX LogP: 2.93

CX LogD: 2.93

Aromatic Rings: 3

Heavy Atoms: 25

QED Weighted: 0.51

Np Likeness Score: -1.36

References

1. Plummer JS, Cai C, Hays SJ, Gilmore JL, Emmerling MR, Michael W, Narasimhan LS, Watson MD, Wang K, Nath R, Evans LM, Jaen JC..  (1999)  Benzenesulfonamide derivatives of 2-substituted 4H-3,1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease.,  9  (6): [PMID:10206542] [10.1016/s0960-894x(99)00095-5]

Source

Source(1):

• Scientific Literature